Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8

Jerusalem, Guy; Prat, Aleix; Salgado, Roberto; Reinisch, Mattea; Saura, Cristina; Ruiz-Borrego, Manuel; Nikolinakos, Petros; Ades, Felipe; Filian, Jeiry; Huang, Ning; Mazzei-Abba, Antonella; Tolaney, Sara M.

doi:10.1016/j.breast.2023.103580

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8

Cited by 7 publications

References 25 publications

CDK4/6 inhibitors: The Devil is in the Detail

CDK4/6 inhibitors: The Devil is in the Detail

Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Contact Info

Product

Resources

About